Interestingly, whereas the cytolytic activity of TCRαβ+ CD8 T cells is a lynchpin of cancer immunotherapies, there are murine tumour-promoting (“T-pro”) CD8 T cells that combine IL-17 production with other traits, including amphiregulin production(115). This evidence concerns the gene CD8A and cancer.